The Clearity Foundation held its Teal Woman 10th Anniversary Celebration on September 16, 2018, at the Paradise Point Resort. The event, themed, “Teal Woman: Celebrating Life. Honoring Courage. Recognizing Progress. Changing the Story for Ovarian Cancer,” helped us to shine … Read more
New research from the University of Illinois at Chicago shows that cancer cells in the fallopian tube affect normal chemical signaling between reproductive tissues and stimulate the release of norepinephrine, a small molecule hormone, from the ovary.
Reported in ACS … Read more
By Doug Wendt
The cancer journey is always overwhelming. No human can come away from the experience unscathed. You begin with a symptom here, a sign there, or maybe something appears on a routine checkup or in imaging. Suddenly, the … Read more
By Rich Haridy
Promising early results are in from a phase 1 clinical trial into the safety and efficacy of a new cancer vaccine. The new treatment is designed to stimulate the immune system into attacking certain cancers known to … Read more
The extent to which the BRCA1 promoter is methylated could signal an ovarian tumor’s susceptibility to PARP inhibitor treatment, a new study has found.
PARP inhibitor treatment has been effective in treating some patients with high-grade serous ovarian carcinoma with … Read more
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but never to a cure. About 15 percent of
… Read moreBy Nicola Davis
Researchers not sure apparent protective effect extends to progestin only products such as mini pill and implants.
Women who use modern forms of the combined pill are at a lower risk of developing ovarian cancer than women … Read more
BY Kelly Irvin
I’ve officially entered the twilight zone. No, not the one Rod Serling spoke of on that classic TV show. This is that murky, dark period when the tumor markers associated with ovarian cancer start creeping up. While … Read more
An analysis of the NRG Oncology clinical trial NRG-GY003 suggests that adding ipilimumab, a monoclonal antibody that targets the protein receptor CTLA-4, to a regimen with the checkpoint inhibitor nivolumab could improve the proportion with tumor response and progression-free survival … Read more
By Diane Mapes
Despite its long-standing nickname, ovarian cancer isn’t really a silent killer. There are symptoms; it’s just that they whisper or are commonly mistaken for something else, like aging or irritable bowel syndrome. As a result of this
By Elaine K. Howley, Contributor
It’s long been said that the Founding Fathers likely grew and possibly enjoyed using marijuana, or Cannabis sativa. But this notion, which was popularized as the fight to legalize marijuana in the early 2000s
… Read moreCancer is never an easy foe, but some types are more stubborn than others. Ovarian cancer is one of the hardest to treat.
But there are signs of progress. Several recent studies have used new combination treatment strategies, including a … Read more
Lawsuits didn’t do it, public shaming didn’t do it, patients and doctors banding together to “free the data” couldn’t do it: For 22 years Myriad Genetics, one of the oldest genetic testing companies, has refused to make … Read more
By: Dr. Laura Shawver, Founder of The Clearity Foundation
Whenever I talk with someone that just received an ovarian cancer diagnosis, it brings back the feelings that I had when I heard the words, “you have ovarian cancer.” I can … Read more
Combining a new targeted cancer drug with chemotherapy has shown promise in an early clinical trial, in patients with ovarian or lung cancer for whom all other treatments had failed.
The combination of targeted drug vistusertib along with paclitaxel chemotherapy … Read more
Researchers at Cancer Research UK, Imperial College London and the University of Cambridge have identified distinct patterns of genetic mutation among patients with ovarian cancer that could help them understand the disease and personalise treatment … Read more
By Health Day News
Testing for gene mutations linked to breast and ovarian cancer is rare among some Medicare patients who have the cancers and qualify for such tests, a new study finds.
Researchers analyzed data from 12 southeastern states … Read more
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.
